**2. Endocrine resistance**

Endocrine resistance is a major obstacle for treatment of HR+ve/HER2−ve MBC. Multiple mechanisms have been implicated. Based on these knowledge we now have a number of targeted therapy that can help overcome this problem. The more clinically relevant mechanisms are discussed as below.
